Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research

BTIG Research reissued their buy rating on shares of Harrow (NASDAQ:HROW) in a research report released on Wednesday, MarketBeat Ratings reports. BTIG Research currently has a $63.00 price target on the stock.

Several other equities research analysts have also recently commented on the stock. Zacks Research cut shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. HC Wainwright raised their price objective on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. William Blair reiterated an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd. Finally, Cantor Fitzgerald reduced their price target on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $71.14.

Harrow Stock Performance

Shares of HROW opened at $34.48 on Wednesday. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -202.81 and a beta of 0.05. Harrow has a 12 month low of $20.85 and a 12 month high of $54.85. The firm has a fifty day simple moving average of $45.14 and a 200 day simple moving average of $43.55. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Larson Financial Group LLC increased its stake in shares of Harrow by 13.1% during the 4th quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock worth $120,000 after purchasing an additional 284 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock valued at $505,000 after purchasing an additional 341 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Harrow by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after purchasing an additional 369 shares during the period. Captrust Financial Advisors grew its holdings in Harrow by 0.5% during the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock worth $3,428,000 after purchasing an additional 376 shares during the period. Finally, Alliancebernstein L.P. increased its position in Harrow by 1.7% during the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock worth $1,422,000 after buying an additional 500 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.